ClinicalTrials.gg
RecruitingNCT04140578ABX-GVUpdated Oct 28, 2019

Antibiotic Prophylaxis in Patients Undergoing GVO

A Phase 4 interventional study of Ertapenem in Gastric Varix, Sepsis and Liver Cirrhoses, sponsored by Taipei Veterans General Hospital, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-10-28.

Sponsored by Taipei Veterans General Hospital, Taiwan · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jan 2017, registered Aug 2019).
  • Started Jan 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Esophageal and Gastric Varices with a site in Taiwan — 3 open to participants now, 3 under way, none of them phase 3. Esophageal and Gastric Varices · Taiwan.

Planned enrollment
3rd of 10
150 · median 120
Started
2017
the only one that year
Phase 4
7 of 11
3 open now
Registered
6th of 11
by date
Lead sponsor
6 of 11
Taipei Veterans General Hospital, Taiwan

Among the 11 studies in Esophageal and Gastric Varices with a site in Taiwan, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 4, and was the 6th registered.

Esophageal and Gastric Varices

150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.

Browse Esophageal and Gastric Varices studies →

Open to participants now

3 of the 11 studies in Esophageal and Gastric Varices with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 20 Esophageal and Gastric Varices studies recruiting now, 13 (65%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Esophageal and Gastric Varices with a site in Taiwan, or all of them as a file.
02

Study summary

We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.

Read the detailed description

Gastric varices is not uncommon is patients with chronic liver diseases including liver cirrhosis and hepatocellular carcinoma. Occurrence of gastric varices (GV) rupture is less often than esophageal varices (EV) but it is characteristic of higher rebleeding rate and mortality and represents an even tougher problem than EV hemorrhage. Endoscopic treatment is an alternative in the management of GV bleeding. Injection sclerotherapy has been applied to arrest GV hemorrhage but it is associated with a high rebleeding rate (50\~90%) and thus is regarded as only a temporary hemostatic measure. The advantage of endoscopic variceal ligation is not suggested due to its high rebleeding rate more than 50%. Endoscopic injection of N-butyl-2-cyanoacrylate, a so-called "tissue glue",is more effective to treat GV bleeding because of more than 90% successful rate to arrest acute bleeding. The theoretical advantages of tissue glue derives from its unique ability to plug the varix lumen immediately after injection into varices. However, its rebleeding rate is still high around 30\~40% and has potential treatment-related morbidity such as embolic and septic complications. Regardless of these disadvantage, the guideline form major international society and Bavenoconsensus recommend GVO as the first treatment of choice for GV bleeding. Therefore how to prevent the potential complications and reduce rebleedingremains an important and practical issue.

With regarding to potential septic infections and rebleeding, the effects of impaired leukocyte function in cirrhotic patients and reduced immunity and increased gut permeability of severe hemorrhagic patients were contributory. In these immunocompromised hosts, when invasive procedure such as GVO is deployed for these patients, the septic complication become un-neglectable, We found (Gastrointest Endosc 2001) more than 1/3 patients undergoing GVO may complicated with bacteremia. Although most of these bacteremia were self-limited, 2% died of sepsis. Moreover, lots of cases were reported due to persistent and recurrent bacterial infections caused by GVO. Antibiotic prophylaxis has been suggested as an integral part for the management of cirrhotic patients with acute varicealbleeding by major international society and Baveno consensus. However, there is no evidence to suggest antibiotic prophylaxis for the patients treated by elective GVO. Therefore we design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.

03

Conditions studied

  • Gastric Varix
  • Sepsis
  • Liver Cirrhoses
  • Fever

Keywords

  • Gastric variceal rebleeding
  • Sepsis
  • cyanoacrylate injection
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with live cirrhosis and/or hepatoma
  2. Aged 20 to 85, who had endoscopy-treatment EV(-)GV(+)or EV\<GV

Exclusion criteria

Exclusion Criteria:

  1. Had a terminal illness of any major organ system,such as heart failure, kindey failure,
  2. Patients recieve antibiotics recently.
  3. Patients suspected infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Antibiotic

    Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration

    Drug: Ertapenem

  • No intervention
    Control

    Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration

Interventions

  • inject from iv drip before endoscopic cyanoacrylateinjection obliteration

    Also known as: Invanz

06

What researchers measure

Primary outcomes

  1. Prevetion of sepsis

    If Antibiotic Prophylaxis can reduce sepsis in Patients Undergoing GVO

    Time frame: 3 years

Secondary outcomes

  1. Rebleeding rate

    If Antibiotic Prophylaxis can reduce GV rebleeding rate

    Time frame: 3 years

  2. Pevention of Refractory bacterial infection

    If Antibiotic Prophylaxis can reduce infection rate in Patients Undergoing GVO

    Time frame: 3 years

  3. Mortality

    If Antibiotic Prophylaxis can decrease mortality in Patients Undergoing GVO

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Veteran General Hospital-Taipei
    Taipei, Taiwan
    Recruiting
    • Ming-Chih Hou · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2017 (actual). Primary completion is estimated for Dec 2030, 167 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Oct 28, 2019
StartActual
Jan 28, 2017
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Oct 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04140578
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Jan 28, 2017
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 28, 2019

Study contacts

Ming-Chih Hou, MD
Contact
mchou@vghtpe.gov.tw
886-2-28712111 ext. 7877
Pei-Chang Lee, MD
Contact
pclee7@vghtpe.gov.tw
886-2-28712111 ext. 3972
Ming-Chih Hou
principal investigator · Taipei Veterans General Hospital, Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertapenem

Start the discussion